drugset / Trial / NCT05653024

INhaled Salbutamol vs Placebo for the Treatment of Acute IgE-mediated Abdominal Pain From Allergic Food REactions

NCT05653024

Phase 3 Terminated 24 enrolled Philippe Bégin
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this study is to assess the efficacy of inhaled salbutamol to treat abdominal pain during food allergic reactions. Patients experiencing abominal pain as a result of a food allergic reaction during a food challenge in the allergy clinic will be invited to participate to the study. They will receive either 8 puffs of salbutamol (asthma inhaler) or 8 puffs of a placebo inhaler. The abdominal pain will then be followed using a numeric scale to see if patients receiving the medication experienced a faster improvement compared to those receiving the placebo.

Timeline

Start
2023-07-01
Primary completion
2025-05-05
Completion
2025-05-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Salbutamol Unknown 800 ug Inhaled

Indications